Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05221021 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 30, 2023 to Dec 30, 2026
    • Study completion date: Jan 30, 2024 to Jan 30, 2027
    v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Jan 30, 2023 to Dec 30, 2023
    • Start date changed from estimate of Jul 30, 2022 to Oct 1, 2022
    • Site details revised
    v3
  3. Start date: Jan 30, 2022 to Jul 30, 2022v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A single site, double-blinded, randomized controlled trial for postmenopausal women with urinary frequency, urgency, nocturia with or without urgency urinary incontinence symptoms. Patient's will be randomized between 0.01% vaginal estradiol cream with placebo oral pill or daily 50 milligrams oral Mirabegron with a placebo vaginal cream for 12 weeks.
Trial Details
NCT Number NCT05221021
Lead Sponsor Walter Reed National Military Medical Center
Conditions
(from sponsor)		 Overactive Bladder Syndrome
Enrollment 152 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov